Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of Toronto

$122,000.00

Artery-on-a-Chip PACE Platform

FY 2009-10

Summary
We will develop an automated platform for routine organ-level investigation and automated screening of small blood vessel segments and their long-term culture. The platform will be based on the proof-of-principle Artery on a Chip (AoC) technology which we secured with a US provisional patent. Resistance arteries were so far reversibly loaded to the AoC device, fixed and functionally tested using manual procedures and irreversible fluidic connections. Loaded resistance arteries showed normal responses to vasoconstrictor and vasodilator stimuli, indicating that microvessel structure and function were maintained. We used aligned multilayer soft lithography to fabricate the proof-of-concept device. Investigating resistance arteries in an automated fashion will likely increase throughput significantly, encourage uniform handling and standardization, and may ultimately result in a major breakthrough in microvascular research. Even more importantly, it may make organ-level based screens applicable to early stages of the drug development process. The technology is applicable to target identification and validation, lead identification and lead optimization and therefore has the potential to significantly reduce time and costs for development and optimization of drug leads. In this project, we develop an improved AoC device that has two key capabilities for long-term artery culture: bubble removal and longitudinal artery stretching. A prototype Pogrammable Artery Culture and Experimentation (PACE) Platform will remove the last manual step of loading individual artery segments by integrating an automated artery loading procedure. A reversible fluidic manifold will integrate the AoC device with the PACE Platform and provide computer-controlled temperature control, artery fixation, perfusion, and superfusion. Time-dependent measurements of artery tone will be performed to obtain scheduled static and dynamic dose-response relationships. The PACE Platform will allow virtually every user to routinely study these very small and fragile arteries using a computer-controlled interface.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
379835-2008
Name nom
Guenther, Axel
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
122000
Program id
I2IPJ
Program nane en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Artery-on-a-Chip PACE Platform
Keyword
NA
Application summary
We will develop an automated platform for routine organ-level investigation and automated screening of small blood vessel segments and their long-term culture. The platform will be based on the proof-of-principle Artery on a Chip (AoC) technology which we secured with a US provisional patent. Resistance arteries were so far reversibly loaded to the AoC device, fixed and functionally tested using manual procedures and irreversible fluidic connections. Loaded resistance arteries showed normal responses to vasoconstrictor and vasodilator stimuli, indicating that microvessel structure and function were maintained. We used aligned multilayer soft lithography to fabricate the proof-of-concept device. Investigating resistance arteries in an automated fashion will likely increase throughput significantly, encourage uniform handling and standardization, and may ultimately result in a major breakthrough in microvascular research. Even more importantly, it may make organ-level based screens applicable to early stages of the drug development process. The technology is applicable to target identification and validation, lead identification and lead optimization and therefore has the potential to significantly reduce time and costs for development and optimization of drug leads. In this project, we develop an improved AoC device that has two key capabilities for long-term artery culture: bubble removal and longitudinal artery stretching. A prototype Pogrammable Artery Culture and Experimentation (PACE) Platform will remove the last manual step of loading individual artery segments by integrating an automated artery loading procedure. A reversible fluidic manifold will integrate the AoC device with the PACE Platform and provide computer-controlled temperature control, artery fixation, perfusion, and superfusion. Time-dependent measurements of artery tone will be performed to obtain scheduled static and dynamic dose-response relationships. The PACE Platform will allow virtually every user to routinely study these very small and fragile arteries using a computer-controlled interface.